Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study. - Mathai DS; Robinson JO; Wagner K; Neitzke-Spruill L; Berrones D; Anderberg JL; Frederick RM; Cruz VZ; Muñoz JS; Latin American Trans-Ancestry INitiative for OCD genomics; Brazilian Obsessive-Compulsive Spectrum Disorder Working Group; Rodriguez CI; et al. (2025)

Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat. - Egger K; Meling D; Polat F; Seifritz E; Avram M; Scheidegger M. (2025)

“So many relationships in the room”: Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy - Ham R; Gardner J; Carter A; Liknaitzky P. (PsyArXiv, 2025)

An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy - University of Southern California (ClinicalTrials.gov, 2025)

“So many relationships in the room”: Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy (PsyArXiv, 2025)

Regional Specificity of the Cingulate Cortex Thickness Association with the Intensity of Psilocybin Experience: A Replication Study - Greguš D; Hlinka J; Tylš F; Viktorin V; Viktorinová M; Bravermanová A; Androvičová R; Andrashko V; Korčák J; Nikolič M; Adámek P; Beneš M; et al. (Research Square, 2025)

Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders. - Havlik JL; Isaac S; Raman P; Tran N; Hidalgo K; Suppes T. (2025)

Psilocybin inhibits formalin-induced nociception through 5-hydroxytryptamine 2A receptor in rats. - Inan S; Morris P; Rawls SM; Daws S. (2025)

Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism - Healing Advocacy Fund (ClinicalTrials.gov, 2025)

Innovative Pharmacological Approaches to Eating Disorder Treatment. - Keshen A; Touyz S; Lacroix E; Hay P; McElroy SL. (2025)

Psilocybin-assisted psychotherapy in adults with depression - A literature review. - Dorczok MC; Mittmann G; Ettl T; Steiner-Hofbauer V. (2025)

Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds. - Hosein MM; Reid MJ; Walser S; Charney S; Fonzo GA; Lewis BR; Yaden DB; Suppes T; Cordner ZA; Barrett FS. (2025)

Electrodynamics of the Psychedelic Experience - Hunt T. (Preprints.org, 2025)

High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats. - Bruno V; López-Canul M; Richardson B; Camarini R; Marcourakis T; Gobbi G. (2025)

Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms. - Schäfer T; Haun F; Rupp B; Hoffmeister D. (2025)

Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study. - Knock E; Siefried KJ; Bedi G; Albert S; Day RO; Ezard N; Ross M; Liknaitzky P; Brett J. (2025)

Psychedelics Relax Priors and Reshape Orbitofrontal Dynamics - Delgado-Sallent C; Ahmed SA; Khawaja-Lopez A; Lee BS; Senne R; Scott BB; Ramirez S. (bioRxiv, 2025)

Reappraisal of the hype and hope offered by psilocybin treatment of depression. - Beaglehole B; Manuel J. (2025)

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. - Lewis BR; Hendrick J; Byrne K; Odette M; Wu C; Garland EL. (2025)

Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US. - Calin A; Burlec AF; Mircea C; Macovei I; Hancianu M; Corciova A. (2025)

Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions. - Alhaj HA; Samara J; Alnamous A; Karima R; Saber-Ayad M. (2025)

PRoMiSS: Psilocybin and the Role of Music in Set and Setting - Johns Hopkins University (ClinicalTrials.gov, 2025)

Compassionate use of psilocybin for treatment-resistant depression in Germany. - Gründer G; Mertens LJ; Jungaberle A; Jungaberle H; Spangemacher M. (2025)

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia - Askey T; Allen-Ross D; Luzyanin D; Lasrado R; Gilmour G; Hunt SP; Tamagnini F; Ahmed M; Stephens GJ; Maiarú M. (bioRxiv, 2025)

Severe Rhabdomyolysis With Stage 3 Acute Kidney Injury After Ayahuasca Use Managed Without Renal Replacement Therapy: A Case Report. - Kermanshah A; Stapleton M; Mauriello CM; Cobas M; Cordoba Torres IT. (2025)

The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial. - Maastricht University (ClinicalTrials.gov, 2025)

Preliminary validation and refinement of the psychedelic aesthetic experience questionnaire. - Hooper JF; Ellingson JM; Hutchison KE. (2025)

Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds. - Pereira Galdino T; Bisneto ABM; Pedro MDS; de Oliveira LC; Luz MA; de Lima AGB; Silva SML; Fook MVL. (2025)

Dynamic myocardial injury and variable hallucination latency in Psilocybe keralensis poisoning: a molecularly confirmed case series from China. - He Z; Tang R; Feng M; Li X; Zhang C; Li J. (2025)

Emerging mechanisms of psilocybin-induced neuroplasticity. - Sonda S; Pendin D; Comai S; De Martin S; Manfredi P; Mattarei A. (2025)

Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal. - Sabbah SG; Li S; Wong S; Le GH; Badulescu S; Hawco C; Rosenblat JD; McIntyre RS. (2025)

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia. - Sapienza J; Spangaro M; Comai S; Sabé M; La Torre J; Buonarroti M; Cavallaro R; Bosia M (International journal of molecular sciences, 2025)

Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism. - Bonniwell EM; Alabdali R; Hennessey JJ; McKee JL; Cavalco NG; Lammers JC; Moore EJ; Franchini L; Orlandi C; McCorvy JD. (2025)

Effective connectivity of the human claustrum: Triple networks, subcortical circuits, and psychedelic modulation - Masjedi NS; Razi A. (bioRxiv, 2025)

Mindset Over Molecule: Comparing Self-Transcendent and Mystical Experiences Across Recreational Psilocybin, MDMA, and Cannabis Use - Chwyl C; Spata A; Lucas W; Luoma JB. (Research Square, 2025)

Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy. - Bélanger A; Chang SL; Stephan JF; Moureaux F; Tapp D; Foxman R; Gagnon P; Hébert J; Farzin H; Dorval M. (2025)

Concomitant use of antidepressants and classic psychedelics: A scoping review. - Tap SC; Thomas K; Páleníček T; Stenbæk DS; Oliveira-Maia AJ; van Dalfsen JH; Schoevers RA. (2025)

N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences. - Vohryzek J; Luppi AI; Atasoy S; Deco G; Carhart-Harris RL; Timmermann C; Kringelbach ML. (2025)

Corrigendum to "Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder" [Neuropharmacology 279 (2025) 110648]. - Gattuso JJ; Kong G; Bezcioglu B; Lu D; Ekwudo MN; Wilson C; Gubert C; Hannan AJ; Renoir T. (2025)

Correction: Therapeutic and legal aspects of psilocybin in cancer-related depression. - Wierzbicka M; Kopczyk R; Gerlach A; Rymaszewska J. (2025)

Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice. - Razidlo J; Cataldo N; Wenthur CJ. (2025)

Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression. - King's College London (ClinicalTrials.gov, 2025)

Processing Intergenerational Trauma With Psilocybin-Assisted Therapy - Rachel Yehuda (ClinicalTrials.gov, 2025)

Characteristics of Ongoing Clinical Trials for Cocaine Use Disorder Registered on Global Clinical Trial Databases. - Gushken F; Fidalgo TM; Tardelli VS. (2025)

Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis. - Wong S; Meckling G; Fabiano N; Lee S; Jones BDM; Shorr R; Dargel A; Davis AK; Fiedorowicz JG; Solmi M; Rosenblat JD; Mulsant BH; et al. (2025)

Blunted psychedelic drug effects in older adults - Aday JS; Carhart-Harris R; Boehnke KF. (PsyArXiv, 2025)

Blunted psychedelic drug effects in older adults (PsyArXiv, 2025)

Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review. - Moreno-Chaparro J; Castañeda-Millán G; Eslava Schmalbach J. (2025)

Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence. - Andrade FRT; Buchborn T; Thalheimer G; Meinhardt MW; Joca S; de Almeida RMM. (2025)

Integrating Holistic Communication into Psychedelic-Assisted Therapies in Hospice and Palliative Care: An Approach Based on Peplau's Theory. - Mesquita Garcia AC; Teixeira F; Maia LO. (2025)

Reply to Gattuso et al.: "Comments on 'Striking long-term beneficial effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming' by Brownstien et al. (2024)". - Brownstien M; Lazar M; Botvinnik A; Pogodin I; Lifschytz T; Lerer B. (2025)

Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial - Khyber Medical University Peshawar (ClinicalTrials.gov, 2025)

Active Constituents of Psilocybin Mushroom Edibles. - van Breemen RB; Simchuk D; Fritzsche B; Huson D; Kuzdzal SA; Ferguson J. (2025)

Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review - Sudhakaran G; Chakraborty S; Aung San; Bharti SAK; Csaba V; Valan Arasu M; Namasivayam SKR; Arockiaraj J. (2025)

Separate or inseparable? Serotonin and dopamine system interactions may underlie the therapeutic potential of psilocybin for anorexia nervosa - McCoy K; Reed F; Conn K; Foldi CJ. (2025)

“Wood-lover paralysis”: Describing a toxidrome with symptoms of weakness caused by some lignicolous “wood-loving” Psilocybe mushrooms - Beck SA; Barlow C; Engel L; Barratt MJ. (2025)

Sample composition and HIV prevention indicator differences using physical vs virtual venue recruitment of men who have sex with men in San Francisco. - Chiu I; Tate M; Trujillo D; Suprasert B; Marr A; Arayasirikul S; Wilson EC; Raymond HF; McFarland W. (2025)

US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022. - Montoy JCC; Wang RC; Coker AR; Smollin CG; Anderson BT. (2025)

Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis. - Avanceña ALV; Vuong L; Kahn JG; Marseille E. (2025)

Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. - McGowan NM; Rucker JJ; Yehuda R; Agrawal M; Modlin NL; Simmons H; Tofil-Kaluza A; Das S; Goodwin GM. (2025)

A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD) - Nathan Brashares Sackett (ClinicalTrials.gov, 2025)

Brain changes associated with depression treatment: a meta-analysis. - Perez GM; Rosenberg BM; Xu W; Oathes DJ. (2025)

Overview and Specificity of Psilocybin Use in the Treatment of Mental Disorders: A Scientometric Analysis. - Fernandes-Nascimento MH; Viana-Ferreira K; Negrão AB. (2025)

Unsupervised Extractive Summarization of Psychedelic User Experience Reports - Islam S; Salam S; Hasan MN. (medRxiv, 2025)

Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics. - Higgins GA; MacMillan C; de Lannoy I; Tyler C; Slassi M. (2025)

Psilocybin: Systematic review of its use in the treatment of depression - Andres-Olivera P; de la Iglesia J; Dominguez-Alvarez E; Soto’Gonzalez P; Rodriguez C; Munaiz-Cossio C; Gonzalez-Bolaños R; Brito-Rey R; Marín-Lorenzo C; Arribas-Simon B. (2025)

Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin. - Purple RJ; Gupta R; Thomas CW; Golden CT; Palomero-Gallagher N; Carhart-Harris R; Froudist-Walsh S; Jones MW. (2025)

Above the threshold, beyond the trip: the role of the 5-HT2A receptor in psychedelic-induced neuroplasticity and antidepressant effects. - Drewko AJ; Habets RLP; Brunt TM. (2025)

Context-dependent structurally informed effective connectivity under psilocybin - Greaves MD; Barta T; Novelli L; Stoliker D; Razi A. (bioRxiv, 2025)

Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion - Zeifman R; Danias G; Agin-Liebes G; Pagni B; Kettner H; Bhat V; Ross S; Erritzoe D; Carhart-Harris R. (Research Square, 2025)

Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice. - Effinger DP; Schalk SS; King JL; Wallingford JR; O'Connell CK; Calderon JR; Kopecky BJ; McCorvy JD; Thompson SM. (2025)

Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures - Centre Hospitalier Universitaire de Nīmes (ClinicalTrials.gov, 2025)

Psychedelics and the Serotonin Hypothesis of Eating Disorders. - Bilenker D; Avena NM. (2025)

Psychedelic use in Poland: prevalence, correlates and social attitudes. - Holas P; Kamińska J. (2025)

Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder. - Gattuso JJ; Kong G; Bezcioglu B; Lu D; Ekwudo MN; Wilson C; Gubert C; Hannan AJ; Renoir T. (2025)

Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study - Centre Hospitalier Universitaire de Nīmes (ClinicalTrials.gov, 2025)

Effects of Psilocybin in Post-Treatment Lyme Disease - Johns Hopkins University (ClinicalTrials.gov, 2025)

Psilocybin-assisted psychotherapy, combined antipsychotic and antidepressant treatment for bipolar depression, duration of birth control pill use and risk of depression, handgrip strength and cognitive function, mood disorders in epilepsy, and mental health issues among physicians. - Koenig HG. (2025)

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder - COMPASS Pathways (ClinicalTrials.gov, 2025)

Attitudes Toward Psychedelic-Assisted Therapies for Cancer-Related Psychosocial Symptoms: A Multi- Stakeholder Analysis - Schuman HD; Deleemans JM; Nguyen T; Savard C; Mina R; Carlson LE. (Research Square, 2025)

Serotonin and psilocybin activate 5-HT1B receptors to suppress cortical signaling through the claustrum. - Madden MB; Schaefgen C; Vedak B; Kwon J; Pedra KSD; Sheats SH; Puche AC; Wolff SBE; Mathur BN. (2025)

Exploring the therapeutic potential of psychedelics in treating substance use disorders. - Li Y; Li H; Wang H; Wang X. (2025)

Psychedelic-assisted therapies for existential and spiritual suffering in palliative care. - Garcia ACM; Maia LO. (2025)

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review. - Hughes B; Mirza S; Ponamala M; Sagaser J; Paredes R; Hematillake N; Tailor C; Khan R; Pemminati S. (2025)

Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource - Singleton SP; Sevchik BL; Lahey A; Cuijpers P; Harrer M; Jones MT; Nayak SM; Strain EC; Vandekar SN; Dworkin RH; Scott JC; Satterthwaite TD. (medRxiv, 2025)

Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions. - Rosa I; Padula LP; Semeraro F; Marrangone C; Inserra A; De Risio L; Boffa M; Zoratto F; Borgi M; Guidotti R; Lorenzo GD; D'Addario C; et al. (2025)

Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome. - Kargbo RB. (2025)

Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. - Ross ML; Iyer R; Williams ML; Boughey M; O'Callaghan C; Hiscock R; Dwyer J. (2025)

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment. - Silczuk A; Madejek RJ; Koweszko T; Mularczyk-Tomczewska P; Adamska E; Gujski M; Szulc A. (2025)

Substance Abuse and Cognitive Decline: The Critical Role of Tau Protein as a Potential Biomarker. - Rebolledo-Pérez L; Hernández-Bello J; Martínez-Ramos A; Castañeda-Arellano R; Fernández-Quezada D; Sandoval-García F; Aguilar-García IG. (2025)

Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks - Jiang Q; Shao L; Yao S; Savalia NK; Gilbert AD; Davoudian PA; Nothnagel JD; Tian G; Hung TS; Lai H; Beier KT; Zeng H; et al. (bioRxiv, 2025)

Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat. - Blest-Hopley G; Pasculli G; Ruffell SGD; Tsang W; Emmanuel O; Pate KM; Kettner H; Roseman L; Erritzoe D; Carhart-Harris R. (2025)

Between enhancement and risk: A critical review of psychedelic microdosing. - Totomanova I; Haijen ECHM; Hurks PPM; Ramaekers JG; Kuypers KPC. (2025)

Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models. - Adeyinka D; Forsyth D; Currie S; Faraone N. (2025)

A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy. - Hultgren J; Hafsteinsson MH; Brulin JG. (2025)

Latent Classes of Lifetime Use of Seven Hallucinogens in the United States. - Meacham MC; Mian MN; Wang RC; Coker AR; Anderson BT; Montoy JCC. (2025)

Therapeutic and legal aspects of psilocybin in cancer-related depression. - Małgorzata W; Kopczyk R; Gerlach A; Rymaszewska J. (2025)

Interventions to support spirituality among adults with cancer: a scoping review. - Miller M; Meyers M; Krainak K; Lewis SP. (2025)

The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: a Survey Based Experiment. - Hitchins K; Reynolds JP. (2025)

519. PSILOCYBIN ASSISTED PSYCHOTHERAPY FOR OBSESSIVE COMPULSIVE DISORDER, BODY DYSMORPHIC DISORDER, AND ANOREXIA NERVOSA: STUDY PROTOCOL (2025)

631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS (2025)

317. PSILOCYBIN DOES NOT INDUCE CONDITIONED PLACE PREFERENCE, BUT MODIFIES BEHAVIORAL PATTERNS IN SPRAGUE-DAWLEY RATS (2025)

164. PSILOCYBIN DURING THE POSTPARTUM PERIOD INDUCES LONG-LASTING ADVERSE EFFECTS IN BOTH MOTHERS AND OFFSPRING (2025)

620. IDENTIFICATION OF BLOOD BIOMARKERS OF PSILOCYBIN-ASSISTED THERAPY TREATMENT RESPONSE FOR GENERALISED ANXIETY DISORDER (2025)

426. THE MGLUR2/3 ANTAGONIST ENHANCES THE BEHAVIORAL AND CELLULAR ANTIDEPRESSANT-LIKE EFFECTS OF PSILOCYBIN AND SCOPOLAMINE (2025)

694. INVESTIGATING THE POTENTIAL OF PSILOCYBIN FOR COMPULSIVE EATING IN A RAT MODEL OF BINGE EATING (2025)

363. DIFFERENTIAL EFFECTS OF PSILOCYBIN AND LISURIDE ON SEROTONIN AND DOPAMINE NEURONAL ACTIVITY AND BEHAVIOR (2025)

229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL (2025)

205. SYNERGISTIC BEHAVIORAL AND NEUROPLASTIC EFFECTS OF PSILOCYBIN-NMDAR MODULATOR ADMINISTRATION (2025)

564. TOWARD AN UNDERSTANDING OF THE THERAPEUTICALLY RELEVANT MECHANISMS OF PSILOCYBIN FOR ANOREXIA NERVOSA (2025)

476. ACUTE AND CHRONIC PSILOCYBIN IN MOUSE MODELS OF PSYCHIATRIC DISORDERS (2025)

597. ARE SIDE EFFECTS NECESSARY FOR ANTIDEPRESSIVE TREATMENT: THE PSILOCYBIN EXPERIENCE (2025)

Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers. - Ley L; Liechti ME; Becker AM; Straumann I; Klaiber A; Holze F; Vogt SB; Arikci D; Schmid Y (Psychopharmacology, 2025)

Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review. - Sulstarova A; Scheuerlein L; Monari S; Seragnoli F; Gabriel T; Preller K; Böge K; Sentissi O; Kaiser S; Solmi M; Kirschner M; Sabé M (Asian journal of psychiatry, 2025)

Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms. - Adebo M; Bonnet M; Laouej O; Defaix C; McGowan JC; Butlen-Ducuing F; David DJ; Poupon E; Tritschler L; Gardier AM. (2025)

Correction to "Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis". (2025)

Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians' Concerns. - Cheung K; Brodie M; Chang SL; Deschamps P; Fallu JS; Farzin H; Hébert J; Stephan JF; Dorval M; Joly Y; P3A Study Group. (2025)

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program. - Liechti ME; Gasser P; Aicher HD; Mueller F; Hawrot T; Schmid Y. (2025)

Psilocybin Prolongs the Neurovascular Coupling Response in Mouse Visual Cortex - Zirkel RT; Isaacson M; Liao C; Yi M; Yamaguchi K; Rivera D; Kuceyeski A; Nishimura N; Kwan AC; Schaffer CB. (bioRxiv, 2025)

Meditation, Psychedelics, and Brain Connectivity: A Randomised Controlled Resting-State fMRI Study of N,N-Dimethyltryptamine and Harmine in a Meditation Retreat - Egger K; Meling D; Polat F; Seifritz E; Avram M; Scheidegger M. (medRxiv, 2025)

Age- and estrous-dependent effects of psilocybin in rats. - Zylko AL; Rakoczy RJ; Roberts BF; Wilson M; Powell A; Page A; Heitkamp M; Feist D; Jones JA; McMurray MS. (2025)

Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL. - Rosa WE; Napolitano S; McAndrew N; Jenkins B; Lichtenthal WG; Applebaum AJ; Breitbart W; Agrawal M. (2025)

Electrophysiological effects of psilocybin co-administered with midazolam - Sutherland MH; Nicholas CR; Lennertz RC; Wenthur CJ; Krause BM; Sauder CJ; Riedner BA; Smith RF; Hutson PR; Raison CL; Banks MI. (bioRxiv, 2025)

Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials. - Bevione F; Lacidogna MC; Lavalle R; Abbate Daga G; Preti A. (2025)

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial - Johns Hopkins University (ClinicalTrials.gov, 2025)

Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD) - King's College London (ClinicalTrials.gov, 2025)

Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-PET Study - Egger K; Bozsak R; Aicher H; Sari H; Poetzsch S; Rominger A; Martin-Soelch C; Dornbierer D; Quednow B; Scheidegger M; Cumming P. (Research Square, 2025)

Molecular Pathways Potentially Involved in Hallucinatory Experiences During Sleep Paralysis: The Emerging Role of β-Arrestin-2. - Rudy LM; Godlewski MM. (2025)

An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions. - Askariyan K; Joghataei MT; Dehghan S; Nohesara S; Riahi Pour L; Mohammadi MH; Ahmadirad N. (2025)

Mechanistic Studies of Psilocybin in Headache Disorders - Yale University (ClinicalTrials.gov, 2025)

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. - Luquiens A; Belahda D; Graux C; Igounenc N; Serrand C; Rochefort P; Mura T; Sergent F. (2025)

Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey. - Rodan SC; Meez N; Lloyd-Hurwitz S; Bedoya-Pérez MA; Suraev A; Sommer N; Greenstien K; Maguire S; McGregor IS. (2025)

The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC) - Emory University (ClinicalTrials.gov, 2025)

Psychedelics, Spirituality, and Fundamentalism: A Brain Network Approach to Cognitive Flexibility and Rigidity. - Yang A; Lv X; Wang H; Wang X. (2025)

Avoiding Stigma and Sensationalism in Therapeutic Psilocybin Communications: Considerations for Reaching Older Patients. - Gillespie CM; Bering JM. (2025)

"I've learned that I'm open-minded to this possibility": A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke. - Cioe PA; Stang GS; Azam D; Dugal S. (2025)

Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatment. - Socoró-Garrigosa M; Perl YS; Kringelbach ML; Erritzoe D; Nutt DJ; Carhart-Harris R; Vohryzek J; Deco G. (2025)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study. - Ludbrook G; Bryson N; Taylor B; Hocevar-Trnka J; Johnson MW; Hirman J; Morrish G; Alexander R; Pollack M. (2025)

Psilocybin as a psychophysical adaptogen in chronic pain rehabilitation. - Cherup NP; Finan PH. (2025)

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality - The University of Texas Health Science Center; Houston (ClinicalTrials.gov, 2025)

Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder - Urban MM; Zillich L; Rieser NM; Herdener M; Vollenweider FX; Spanagel R; Preller KH; Meinhardt MW. (bioRxiv, 2025)

The polypharmacology of psychedelics reveals multiple targets for potential therapeutics. - Jain MK; Gumpper RH; Slocum ST; Schmitz GP; Madsen JS; Tummino TA; Suomivuori CM; Huang XP; Shub L; DiBerto JF; Kim K; DeLeon C; et al. (2025)

Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials. - Kittur ME; Burgos M LA; Jones BDM; Blumberger DM; Mulsant BH; Rosenblat JD; Husain MI. (2025)

The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal. - Fernández-Borkel T; Borkel LF; Rojas-Hernández J; Hernández-Álvarez E; Quintana-Hernández DJ; Ponti LG; Henríquez-Hernández LA. (2025)

Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis. - Cheung K; Propes C; Graziosi M; Patch K; Yaden DB. (2025)

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases - Heller NH; Barrett FS; Buchborn T; Collerton D; Dupuis D; Halberstadt AL; Jardri R; Noorani TN; Preller KH; Taylor J; Waters F; Winston B; et al. (PsyArXiv, 2025)

Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review. - Sudhakaran G; Chakraborty S; Kumar A; Bharti SAK; Csaba V; Valan Arasu M; Namasivayam SKR; Arockiaraj J. (2025)

Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers. - Nadeem Z; Parker S; McGovern H; Sebben B; Oestreich LK. (2025)

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases (PsyArXiv, 2025)

Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury. - Plummer Z; Allen J; Brand J; Mayo LM; Shultz SR; Christie BR. (2025)

Equitable access to psilocybin-assisted psychotherapy in New Zealand. - Lacey C. (2025)

Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics. - Swieczkowski D; Kwaśny A; Ciurkowska P; Pruc M; Szarpak L; Cubała WJ. (2025)

A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction. - Glenn DL; Choi SH; Zimmerman RS. (2025)

Exploring the Frontiers of Psychedelics: A New Chromatographic Method for Detection and Quantification of Psilocybin and Psilocin in Psilocybe cubensis Mushrooms. - Pereira Galdino T; Oliveira LC; Luz MA; Costa Barbosa R; Torres MCM; Sivieri K; Fernandes PA; Santos ML; Lima AGB; Silva SML; Fook MVL. (2025)

Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action. - Miller EA; Capone C; Eaton E; Swift RM; Haass-Koffler CL. (2025)

Treatment with LSD and psilocybin at the department of psychiatry at Frederiksberg Hospital in Denmark from 1960 to 1973: an analysis of 324 cases. - Larsen JK; Kølbæk P; Østergaard SD. (2025)

Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception. - Muller S; Cavanna F; de la Fuente L; Bruno N; D'Amelio TA; Pallavicini C; Tagliazucchi E. (2025)

Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies - Rajwani K; Almonte MT; Feroz F; Hokanson J; Jacobs E; Savulescu J; Singh I; Yaden DB; Earp BD. (Wellcome Open Res, 2025)

Psilocybin treatment extends cellular lifespan and improves survival of aged mice. - Kato K; Kleinhenz JM; Shin YJ; Coarfa C; Zarrabi AJ; Hecker L. (2025)

The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of Psilocin. - Zhang M; Zhai H; Yang L; Li H; Wang X; Wang X. (2025)

Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India. - Joga R; Yerram S; Patnam JD; Choudhary KK; Varpe P; Raghuvanshi RS; Srivastava S. (2025)

An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression - Szigeti B. (PsyArXiv, 2025)

Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: a qualitative-quantitative approach. - Jylkkä J; Väyrynen H; Lin E; Walldén C; Krabbe A; Kähönen J; Sikka P. (2025)

An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression (PsyArXiv, 2025)

Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models - Gregory NS; Girard TE; Ram A; Casey AB; Malenka RC; Tawfik VL; Heifets BD. (bioRxiv, 2025)

The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine. - Park D; Lee G; Lee WG; Kim B; Lee Y; Kim JW. (2025)

Exploring Jordanian Physicians' and Medical Students' Perspectives on Ketamine and Psychedelic-Assisted Therapies: An Insight from the Middle East. - Ahmed KE; Abu Nasrieh D; Banihani HA; Obaidat MF; Mazzawi T; Al-Tarawneh AK; Bani Mustafa R; Al Kayed Z. (2025)

Effects of Psilocin and Psilocybin on Human 5-HT4 Serotonin and H2 Histamine Receptors in Perfused Hearts of Transgenic Mice. - Braekow P; Neumann J; Kirchhefer U; Gergs U. (2025)

Behavioural and pharmacological evaluation of the psilocybin analogue baeocystin in Wistar rats. - Danda H; Mazochová K; Šíchová K; Mazoch V; Olejníková-Ladislavová L; Syrová K; Jurásek B; Cihlářová P; Jurok R; Páleníček T; Kuchař M. (2025)

Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging - Tolle HM; Luppi AI; Lawn T; Roseman L; Nutt D; Carhart-Harris RL; Mediano PAM. (bioRxiv, 2025)

Is There More to Magic Mushrooms than Psilocybin? - Johnson-Groh M. (2025)

Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties. - Atiq MA; Baker MR; Voort JLV; Vargas MV; Choi DS (Psychopharmacology, 2025)

Exploring serotonergic psychedelics as a treatment for personality disorders. - Carrithers BM; Roberts DE; Weiss BM; King JD; Carhart-Harris RL; Gordon AR; Pagni BA; Moreau M; Ross S; Zeifman RJ (Neuropharmacology, 2025)

Development and validation of an analytical method for the determination of select 4-position ring-substituted tryptamines in plasma by liquid chromatography-tandem mass spectrometry. - Pego AMF; Schoffner M; Sammeta VR; Naeem M; Manke DR; Chadeayne A; Glatfelter GC; Baumann MH; Concheiro-Guisán M. (2025)

Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises. - Harding R; Singer N; Wall MB; Hendler T; Erritzoe D; Nutt D; Carhart-Harris R; Roseman L. (2025)

4-HIAA Blocks Methamphetamine-Induced Conditioned Place Preference in Mice Through Modulation of the 5-HT Pathway in the Nucleus Accumbens. - Wu Y; Ran J; Mo J; Wang J. (2025)

Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings. - Calnan M; Blest-Hopley G; Busch C; Adams M; Ruffell SGD; Piper T; Roseman L; Kettner H; Carhart-Harris R. (2025)

What fMRI studies say about the nature of the psychedelic effect: a scoping review. - Beneš M; Páleníček T; Horáček J. (2025)

Efficient Acyloxymethylation of Psilocin and Other Tryptamines Yielding ACOM Prodrugs for Psychedelic-Assisted Therapy. - Stirn J; Klein CD. (2025)

Psychedelic drugs for the treatment of substance use disorders. - Sofuoglu M; De Aquino JP; MacLean RR (Expert review of clinical pharmacology, 2025)

Chemical Composition and Biological Activities of Psilocybe Mushrooms: Gaps and Perspectives. - Luz MA; Guedes HVS; Bisneto ABM; Jesus RA; Galdino TP; Oliveira LC; Afonso VI; Fook MVL; Lima AGB; Silva SML; Torres MCM. (2025)

Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis. - Hieronymus F; López E; Werin Sjögren H; Lundberg J. (2025)

Synthesis of Psilocin, Psilocybin and 5-MeO-DMT Succinate, All Labelled With Carbon-14 at the Indole 2-Position. - Brown R; Hamilton NM; Mallon C; Stevenson J; Faley MT; Kargbo RB; Sherwood AM; Upeandran B. (2025)

Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances. - Christen SE; Bekka E; Schmid Y; Benowitz NL; Liakoni E. (2025)

Untargeted analysis of psilocybin and non-psilocybin mushrooms using liquid chromatography quadrupole time of flight mass spectrometry - Islam S; Liden T; Goff R; Schug KA. (2025)

Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms. - Modlin NL; Jessica L MK; Sarang M; Siebenaler L; Maggio C; Pick S; Williamson V; Cleare A; Rucker J. (2025)

Natural hallucinogens of fungal and animal origin: action and potentialapplications - a narrative review. - Ciszowski K; Ziaja A; Niedzielska-Andres E; Pomierny-Chamioło L. (2025)

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression. - Brudner RM; Kaczmarek E; Blainey MG; Schulz-Quach C; Meshkat S; Doyle Z; Lipsitz O; Offman H; Sethi R; Weiglein G; McIntyre RS; Rosenblat JD. (2025)

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study. - Pellegrini L; Fineberg NA; O'Connor S; De Souza AMFLP; Godfrey K; Reed S; Peill J; Healy M; Rohani-Shukla C; Lee H; Carhart-Harris R; Robbins TW; et al. (2025)

Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis. - Schuman HDM; Savard C; Mina R; Barkova S; Conradi HSW; Deleemans JM; Carlson LE. (2025)

Paper spray and direct mushroom spray mass spectrometry methods for the analysis of psycho-neurological disorder toxins. - Luo W; Dai Q; van Beek TA; Zuilhof H; Chen B; Chen Z; Salentijn GI. (2025)

A Scoping Review of Research in Naturalistic Studies with Psychedelics. - Carvalho LC; Encantado J; Kettner H; Timmermann C; Veiga D; Teixeira PJ. (2025)

Visual Surround Suppression and Perceptual Expectation Under Psilocybin - University of Minnesota (ClinicalTrials.gov, 2025)

Australia's psychedelic experiment: reflections from a psychiatrist clinical researcher. - Bayes A. (2025)

Psilocybin Modulates TPJ Effective Connectivity during Out-of-Body Experiences - Stoliker D; Bernasconi F; Blanke O; Razi A. (medRxiv, 2025)

Serotonin 5-HT2A receptor expression is chronically decreased in the anterior cerebral cortex of male rats following repetitive low-level blast exposure. - De Gasperi R; Perez Garcia G; Gama Sosa MA; Perez GM; Abutarboush R; Kawoos U; Hof PR; Zhu CW; Ahlers ST; Elder GA. (2025)

Selective Phosphorylation of Phenols and Benzenediols by the Kinase PsiK and Variants Thereof. - Kim A; Morato NM; Saha P; Eyimegwu PN; Niyaz AA; Huang R; Cooks RG; Phelan RM; Lewis JC. (2025)

The Clinical Applications of Psilocybin Therapies and Post-COVID Syndrome: A Comprehensive Narrative Review. - Mathew A; Dongre R; Kim SH; Turner J; Mathew A; Cherryholmes E; Mehrinfar M; Kamprath S. (2025)

Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows. - Vinarcsik L; Smoller C; Grossberg G. (2025)